NEOADJUVANT HIGH-DOSE METHOTREXATE, CISPLATIN, AND DOXORUBICIN FOR THE MANAGEMENT OF PATIENTS WITH NONMETASTIC OSTEOSARCOMA

被引：0
|
作者：
WEINER, MA
HARRIS, MB
LEWIS, M
JONES, R
SHERRY, H
FEURER, EJ
JOHNSON, J
LAHMAN, E
机构：
[1] MT SINAI MED CTR,DEPT NEOPLAST DIS,NEW YORK,NY 10029
[2] MT SINAI MED CTR,DEPT ORTHOPED,NEW YORK,NY 10029
[3] MT SINAI MED CTR,DEPT BIOMATH SCI,NEW YORK,NY 10029
[4] HOSP JOINT DIS,INST ORTHOPED,BONE TUMOR SERV,NEW YORK,NY 10003
来源：
CANCER TREATMENT REPORTS | 1986年 / 70卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1431 / 1432
页数：2
相关论文
共 50 条
  • [21] Switching chemotherapy in adult osteosarcoma patients with poor necrosis rates post neoadjuvant methotrexate, cisplatin, and doxorubicin (MAP)
    O'Kane, Grainne
    Cadoo, Karen Anne
    Walsh, Elaine
    O'Keane, Conor
    O'Toole, Gary
    Dudney, Sean
    Carney, Desmond
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction
    Bar Sela, G
    Tsalic, M
    Gaitini, D
    Steiner, M
    Haim, N
    JOURNAL OF CHEMOTHERAPY, 2002, 14 (06) : 623 - 626
  • [23] DOSAGE ADJUSTMENT OF HIGH-DOSE METHOTREXATE IN ADULT OSTEOSARCOMA
    PIGNON, T
    LACARELLE, B
    GUILLET, P
    DUFFAUD, F
    CATALIN, J
    DURAND, A
    FAVRE, R
    BULLETIN DU CANCER, 1994, 81 (11) : 976 - 978
  • [24] Methotrexate (MTX) serum peak monitoring in patients with osteosarcoma treated with high-dose methotrexate chemotherapy
    Landre, Thierry
    Cras, Audrey
    El Ghessassi, Ibrahim
    Mourez, Thomas
    Martre, Helene Sauvageon
    Faure, Pierre
    PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 499 - 499
  • [25] Polish Paediatric Solid Tumours Study Group -: Results of randomised trial comparing high-dose methotrexate plus doxorubicinto doxorubicin plus cisplatin in nonmetastatic osteosarcoma patients
    WoYniak, Wojciech
    Rychowska-Pruszyniska, Magdalena
    Korzon, Maria
    Krawczyk-Rybak, Martyna
    Wysocki, Mariusz
    Wachowiak, Jacek
    Eugowska, Iwona
    Chybicka, Alicja
    Raciborska, Anna
    Szafraniski, Andrzej
    Szymborska, Agnieszka
    Bilska, Katarzyna
    Karwacki, Marek
    Kowalczyk, Jerzy
    Balcerska, Anna
    Balwierz, Walentyna
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 421 - 421
  • [26] CELLULAR IMMUNITY DURING AND AFTER HIGH-DOSE METHOTREXATE THERAPY IN PATIENTS WITH OSTEOSARCOMA
    RELLA, W
    LEBER, H
    KOTZ, R
    WIENER KLINISCHE WOCHENSCHRIFT, 1977, 89 (22) : 751 - 755
  • [27] High-dose methotrexate population pharmacokinetic and pharmacogenetic analysis in pediatric patients with osteosarcoma
    Lui, G.
    Treluyer, J. M.
    Fresneau, B.
    Le Deley, M. C.
    Le Teuff, G.
    Brugieres, L.
    Bouazza, N.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 42 - 43
  • [28] Feasibility and tolerance of high-dose methotrexate (HDMTX) in older patients with osteosarcoma.
    Norman, Aurora
    Siontis, Brittany L.
    Ho, Thanh P.
    Houdek, Matthew T.
    Okuno, Scott H.
    Robinson, Steven Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Nonmetastatic osteosarcoma of the extremity: Results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response
    Ferrari, S
    Mercuri, M
    Picci, P
    Bertoni, F
    del Prever, AB
    Tienghi, A
    Mancini, A
    Longhi, A
    Rimondini, S
    Donati, D
    Manfrini, M
    Ruggieri, P
    Biagini, R
    Bacci, G
    TUMORI, 1999, 85 (06) : 458 - 464
  • [30] Neoadjuvant multidrug chemotherapy including High-Dose Methotrexate modifies VEGF expression in Osteosarcoma: an immunohistochemical analysis
    Barbara Rossi
    Giovanni Schinzari
    Giulio Maccauro
    Laura Scaramuzzo
    Diego Signorelli
    Michele A Rosa
    Carlo Fabbriciani
    Barone Carlo
    BMC Musculoskeletal Disorders, 11
12345